TMDX

TransMedics Group, Inc.

Company Overview

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

SectorHealthcare
IndustryMedical - Devices
Market Cap$2.5B
Last DividendNone
Employees898
CEOWaleed H. Hassanein

Valuation

Current Price$70.74
Fair Value?$000.00
Valuation?No valuation
Current PE ?16.11
Hist. PE ?N/Aⓘ
EPS (TTM) ?4.39
Forward EPS Growth ?54.89%
Historical Growth ?58.56%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro

Price?

EPS?

Revenue?

Equity?

Pro

Available on the Pro plan

Free Cash Flow?

Pro

Available on the Pro plan

Long Term Debt?

Pro

Available on the Pro plan

Net Profit?

Pro

Available on the Pro plan

Shares Outstanding?

Pro

Available on the Pro plan

Last updated: 10/23/2026, 11:11:05 PM